InheRET: A SaaS solution to identify patients at increased risk for hereditary disease.

点击翻译按钮获取中文摘要

PROJECT SUMMARY This project is to expand the InheRET Inherited Risk Evaluation Tool to include recommendations for testing of patients at increased risk for hereditary disease, adding patient navigation features and customizable database entries for healthcare providers. This will include the development, integration and testing of InheRET 3.0 followed by pilot testing in 5 diverse clinics. InheRET's aim is to quickly and easily identify individuals at increased risk for hereditary diseases enabling them to access downstream care, reducing morbidity and mortality. InheRET's unique features reduces clinical ascertainment barriers, streamlines workflows and enhances profitability within health systems. The aims for this project are to complete in silico (computer generated) testing of the cognitive computing engine of InheRET followed retrospective testing and finally, pilot testing in a variety of clinical settings to determine if any additional changes are needed to the product prior to commercialization. In addition, we will expand the integration of the InheRET program with an EPIC electronic health record system, providing hard and/or soft alerts for providers as patient reports become available. Success will be determined if we achieve 100% concordance with the in silico testing (i.e. the cognitive computing engine functions correctly), 98% concordance with clinical determinations in the clinical pilot testing, and 100% concordance in the integration testing (all patient reports are appropriately and seamlessly routed to the proper medical records). Our primary objective is to produce an accurate, easy-to-use and understandable report to ensure patients who may unknowingly harbor inherited genetic mutations are identified, thereby enabling them to access genetic counselors and testing along with appropriate downstream care. While both patient and physician reports are provided, the physician reports will be enhanced by providing recommended genes for testing with streamlined ordering processes. By doing so, patients can reduce their risk of disease, receive tailored treatment if they incur disease, and reduce overall mortality.